Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

The demand for weight loss drugs like Ozempic and Wegovy has led to a flood of fake drugs hitting the market. However, these ...

Unbelievable markdowns. A simple online search for semaglutide, the active ingredient in Ozempic or Wegovy, can lead consumers down a rabbit hole of seemingly reputable online pharmacies in search of ...

In the study, 33.4% of patients taking Wegovy were admitted, compared to about 37% in the placebo cohort. Use of the weight loss drug was also linked to shorter hospital stays. Eli Lilly and Novo ...

No matter how much she ate, she never felt satisfied. But after starting a non-FDA approved GLP-1 agonist—an injectable drug ...

The national use of weight loss drugs like Ozempic and Wegovy more than doubled as bariatric surgery frequency dropped by ...

Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...

Wegovy: Approved for chronic weight management in adults with ... An oral form of semaglutide approved for improving blood ...

U.S. Customs and Border Protection officers in Cincinnati recently seized more shipments containing unapproved medications.

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...